AzTrials
AzTrials

CancerNCT04607330

Protein Top-up Acceptability Study for Patients With Increased Protein Needs

A study testing High protein liquid in people with Cancer and Neurological Injury, run by Nutricia UK Ltd at 2 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this prospective, single-arm intervention study is to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Cancer, Neurological Injury, Respiratory Disease
What is being tested?
High protein liquid
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
2 sitesUnited Kingdom
Study dates
28 Oct 2020to 28 Jun 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years of age and older.
  • Patients under the care of a Dietitian requiring oral or enteral nutritional support, with -increased protein needs.
  • To receive a minimum of 1 x 40ml HPLM daily (orally or via enteral tube) while on the study.
  • Informed consent obtained from the patient

Who cannot join

  • Total parenteral nutrition (100% of requirements).
  • Patients with major hepatic dysfunction (i.e. decompensated liver disease).
  • Patients with major renal dysfunction (i.e. requiring filtration or Stage 4/5 chronic kidney disease (CKD)).
  • Participation in other studies within 1 month prior to entry of this study.
  • Patient with severe lactose intolerance.
  • Pregnant or lactating.
  • Patient lacks capacity to consent for themselves.

Trial locations and contacts

2 sites in 1 country.

United Kingdom2 sites
  • University Hospitals Bristol

    Bristol, BS2 8HW

  • Western Sussex Hospitals NHS Trust

    Worthing, West Sussex, BN11 2DH

Other trials in United Kingdom

About this study

Official title: Acceptability of a Ready to Use, Low Calorie, Low Volume, High Protein Liquid for Patients With Increased Protein Needs

The aim of this prospective, single-arm intervention study is to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs.

Read the detailed description

Increased protein needs are frequently observed in disease and can be difficult for patients to achieve where oral food intake is compromised.Where a standard ONS or enteral tube feed cannot meet the needs of patients, a modular feed can be added to the regimen, a low calorie, low volume, ready to use, high protein liquid may help meet protein needs while preventing caloric overfeeding.

40 patients will be recruited in an attempt to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs. After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance and dietary intake with their currently prescribed nutritional regimen, each patient will receive the high protein liquid feed daily for 28 days.

Being tested
High protein liquid
Medical subject headings
Neoplasms, Trauma, Nervous System, Respiration Disorders, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High protein liquidOther

    After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.

Study groups in NCT04607330
Study groupRoleWhat they receive
High protein liquidExperimentalA ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
Receives: Other: High protein liquid

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Acceptability

    Acceptability of the patients existing feeding regimen (including any protein module use) will be assessed on day 1, baseline period. Acceptability with the study product will be assessed at the end of the intervention period using a standardised questionnaire completed by the patient.

    Measured: 2 days (days 1 and 29)

Secondary outcomes (10)
  1. Compliance

    Compliance with the recommended intake of patients' currently prescribed high protein modular feed (if an existing user) and feeding regimen overall will be assessed separately at baseline. Similarly, compliance with the study product will be assessed daily throughout the intervention period and weekly when considering the patients feeding regimen overall. Compliance data will not be used in calculations for nutrient intake. For daily compliance questions, patients will be asked to record how many servings are taken compared to that recommended by their Health Care Professional (HCP). The daily amount prescribed by the HCP managing the patients care will be recorded at the start of the study and any changes to this prescription during the study will be noted. To strengthen compliance measures for the HPLM only, a count of the HPLM will be conducted on day 29 and compared to amount prescribed at baseline.

    Measured: 29 days

  2. Change in Gastrointestinal tolerance

    Gastrointestinal tolerance (including symptoms of diarrhoea, constipation, nausea, vomiting, abdominal pain, bloating, flatulence and burping) and information about bowel movements will be assessed during baseline (day 1), and on days 8, 15 and 29 of the intervention period using a standardised gastrointestinal tolerance questionnaire. This will be completed by the patient or their carer (using the scale: none, mild, moderate, severe symptoms)

    Measured: 4 days (day 1, 8, 15 and 29)

  3. Change in Nutrient Intake (24-hour dietary recall)

    During recruitment, on a per patient and condition specific basis, the patients managing Dietitians will calculate estimated energy and protein requirements as per standard dietetic practice. Intake of all nutrition provided (including the HPLM, other enteral tube feeds, foods, drinks and oral nutritional supplements) will be recorded at baseline and at the end of the intervention period via 24 hour dietary recall. Actual intakes will subsequently be compared against Dietitians calculated estimated energy and protein requirements and percentage achievements of these requirements will also be calculated. This will include details of feeding regimens as required. Trained research staff will subsequently analyse all records utilising a nutritional software package (Nutritics Professional v3.09, Nutritics, Ireland) for macro- and micro-nutrient intakes.

    Measured: 2 days (day 1 and 29)

  4. Change in Physical Function (30-s Chair Stand Test)

    To assess physical function, the 30-s Chair Stand Test will be completed during baseline (day 1) and at the end of the intervention period (day 29). Patients will be requested to stand up and sitting down from a chair as many times as possible within 30 seconds. This will be performed 3 times (with a 1 min rest in between sets) and an average score taken. A standard chair (with a seat height of approximately 40 cm) without armrests will be used. Initially, patients will be seated with their back in an upright position and arms folded across the chest. They will need to look straight forward and begin once ready and maintain their own preferred speed.

    Measured: 2 days (day 1 and 29)

  5. Change in MUST Screening

    The risk of malnutrition will be assessed during baseline (day 1) and at the end of the intervention period (day 29) using the Malnutrition Universal Screening Tool (MUST). MUST is a five-step screening tool to identify adults, who are malnourished, at risk of malnutrition (undernutrition), or obese. Trials sites will receive a guide and flowchart to help quantify MUST score.

    Measured: 2 days (day 1 and 29)

  6. Change in Height

    Height will be captured, wherever possible, using standard measures to the nearest 0.1cm.

    Measured: 2 days (day 1 and 29)

  7. Change in Weight

    Weight will be determined to the nearest 0.1kg, using portable scales, shoeless and wearing light weight clothing.

    Measured: 2 days (day 1 and 29)

  8. Dietetic Goal

    The dietetic goal of each patient will be recorded at baseline by the Dietitian and achievement of this goal (via yes/no responses) in the view of the Dietitian will be assessed at the end of the intervention (day 29).

    Measured: 1 day (day 29)

  9. Adverse events

    All adverse events will be recorded, throughout the study.

    Measured: 29 days (assessed daily)

  10. Patient history

    A detailed patient history will be recorded at baseline to assess previous compliance, relevant clinical issues, diagnosis, medication prescribed, details of current and previous feeding regimens, feeding history, need for protein supplementation and any other relevant clinical information related to the patient's condition or diet.

    Measured: 1 day (day 1)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2020
  2. Study start28 Oct 2020
  3. Primary completion30 May 2022
  4. Study completion28 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
Single-arm intervention study to evaluate the acceptability (compliance, gastrointestinal tolerance and palatability) of the high protein liquid feed in patients with elevated protein needs.
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04607330
Sponsor's protocol ID
PROSHT20'
Status last verified
Apr 2023
First submitted
21 Sep 2020
Last updated
20 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing High protein liquid in people with Cancer and Neurological Injury, run by Nutricia UK Ltd at 2 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Acceptability (time frame: 2 days (days 1 and 29)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in